• TrialScope

  Participated · Equity · Jun 2014

  TrialScope delivers an integrated platform that enables clinical trial sponsors to comply with legislation and internal policy, address disclosure risk, register trials, and disclose results globally. The product emphasizes clinical trial transparency and managing global registration and disclosure processes. The company serves top biotech and pharmaceutical companies and highlights cost savings and risk reduction while ensuring compliance. TrialScope's management says the solution suite increases sponsor productivity and helps accelerate time to market within a heavily regulated environment. To support expansion, the company secured financing tied to its monthly recurring revenue. Proceeds will be used to fund growth and working capital needs. TrialScope provides tools and systems to improve clinical trial processes and mitigate registry and lifecycle risk. The company is described as a global leader in clinical trial transparency and compliance. Led by CEO Mike Forgash, TrialScope offers technology and services focused on clinical trial registration and transparency. It is using proceeds from the financing to finance the acquisition of substantially all Deloitte Analytics LLC assets, including the PharmaCM business and key personnel. PharmaCM is a content management platform that addresses registry and lifecycle challenges for life sciences companies. TrialScope raised more than $10M in the financing round.

No current team members are available.